Abstract
During the last 30 years, clinical trial methodology has evolved from the interface of epidemiology, biostatistics, and clinical medicine to a specialty with its own experts, terminology, computer programs, books, and journals. During much of this time, randomized clinical trials for the treatment of primary biliary cirrhosis (PBC) were being conducted1–5. This chapter discusses three important issues in the design of therapeutic trials of PBC: choice of the primary research issue, sample size and power calculations, and choice of the primary response variable. It is hoped that consideration of these issues will result in well-planned trials in PBC and will serve a note of caution to investigators before embarking on a trial that may not be capable of achieving its goal.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 1976;70(5):656–60.
Dickson ER, Fleming TR, Wiesner RH, et al.Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med 1985;312(16):1011–15.
Neuberger J, Christensen E, Portmann B, et al.Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis. Gut 1985;26(2):114–19.
Bodenheimer H Jr, Schaffner F, Pezzullo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 1988;95(1):124–9.
Kaplan MM, Ailing DW, Zimmerman HJ, et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 1986;315(23)1448–54.
Frieman JA, Chalmers TC, Smith H Jr, Kucbler RR. The importance of beta, the type ll error and sample size in the design and interpretation of the randomized control trial: survey of 71 “negative” trials. N Engl J Med 1978;299:690–4.
Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials, 3rd edn. St. Louis, MO: Mosby-Year Book Inc.; 1996:361.
Everhart JE, Lombardero M, Detre KM, e1 al. Increased waiting time for liver transplantation results in higher mortality. Transplantation. 1997;64(9):1300–6.
Heathcote EJ, Cauch-Dudek K, Walker V, et al.The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22(3):759–66.
Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA—PBC Study Group. N Engl J Med 1994;330(19):1342–7.
Lindor KD, Dickson ER, Jorgensen RA, et al.The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 1995;22(4):1158–62.
Combes B, Carithers RL Jr, Maddrey WC, et al.A randomized, double-blind placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22(3):759–60.
Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113(3):884–90.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Everhart, J. (1998). New clinical trials in primary biliary cirrhosis: design and endpoints. In: Lindor, K.D., Heathcote, E.J., Poupon, R. (eds) Primary Biliary Cirrhosis. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4884-9_20
Download citation
DOI: https://doi.org/10.1007/978-94-011-4884-9_20
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6047-9
Online ISBN: 978-94-011-4884-9
eBook Packages: Springer Book Archive